| 25.15 0.73 (2.99%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 29.76  |
1-year : | 34.76 |
| Resists | First : | 25.47 |
Second : | 29.76 |
| Pivot price | 19.87 |
|||
| Supports | First : | 19.15 |
Second : | 15.25 |
| MAs | MA(5) : | 22.31 |
MA(20) : | 18.99 |
| MA(100) : | 17.1 |
MA(250) : | 20.52 |
|
| MACD | MACD : | 1.7 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 92.7 |
D(3) : | 91.8  |
| RSI | RSI(14): 82.5 |
|||
| 52-week | High : | 36.9 | Low : | 13.82 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SMMT ] has closed above the upper band by 8.8%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 181.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 25.5 - 25.57 | 25.57 - 25.66 |
| Low: | 23.84 - 23.93 | 23.93 - 24.03 |
| Close: | 24.99 - 25.13 | 25.13 - 25.28 |
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Fri, 17 Apr 2026
Board seats, pay and equity plan on ballot at Summit Therapeutics (NASDAQ: SMMT) - Stock Titan
Fri, 17 Apr 2026
Evercore Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Fri, 17 Apr 2026
SMMT Technical Analysis | Trend, Signals & Chart Patterns | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Thu, 16 Apr 2026
Summit Therapeutics Inc Stock (SMMT) Moved Up by 12.03% on Apr 16: Drivers Behind the Movement - TradingKey
Thu, 16 Apr 2026
SMMT Stock Up 24% in Three Months: Here's What You Need to Know - Yahoo Finance
Tue, 14 Apr 2026
How Summit Therapeutics Inc. (SMMT) Affects Rotational Strategy Timing - Stock Traders Daily
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 775 (M) |
| Shares Float | 134 (M) |
| Held by Insiders | 82.6 (%) |
| Held by Institutions | 15.5 (%) |
| Shares Short | 36,120 (K) |
| Shares Short P.Month | 37,870 (K) |
| EPS | -1.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.85 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -115.3 % |
| Return on Equity (ttm) | -206.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.41 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -323 (M) |
| Levered Free Cash Flow | 84 (M) |
| PE Ratio | -17.47 |
| PEG Ratio | 0 |
| Price to Book value | 29.58 |
| Price to Sales | 0 |
| Price to Cash Flow | -60.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|